Clinical Trials
23 trialsA Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)
Regeneron Pharmaceuticals
Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer
M.D. Anderson Cancer Center
A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)
Regeneron Pharmaceuticals
EDGE-Lung
Gilead Sciences
HS-IT101 Injection for Advanced NSCLC
Qingdao Sino-Cell Biomedicine Co., Ltd.
SSGJ-707 in Advanced Non-Small Cell Lung Cancer
Shenyang Sunshine Pharmaceutical Co., LTD.
Efficacy and Safety of IBI351 in Combination With Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation
Innovent Biologics (Suzhou) Co. Ltd.
Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in India
Pfizer
Phase 2 Study of S-1 in Combination With Cisplatin as 1st Line Therapy in Advanced Non-Small Cell Lung Cancer
Taiho Oncology, Inc.
Phase 2 Study of S-1 as 2nd Line Therapy in Advanced Non-Small Cell Lung Cancer
Taiho Oncology, Inc.
Surufatinib or Surufatinib Combined With Vinorelbine for Non-Small Cell Lung Cancer
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Safety, Tolerability, and Efficacy of GLS-012 and GLS-010 in Patients With Advanced Non-Small Cell Lung Cancer
Guangzhou Gloria Biosciences Co., Ltd.
Envafolimab Plus Docetaxel In Combination With or Without Trilaciclib Versus Docetaxel in Advanced NSCLC
Fudan University
A Single-Arm Phase II Clinical Study of Pemigatinib in the Treatment of Advanced Non-Small Cell Lung Cancer Patients With FGFR Alterations Who Have Failed Standard Therapy
The First Affiliated Hospital of Xiamen University
TORCH
National Cancer Institute, Naples
DISTAL-2
National Cancer Institute, Naples
Nimotuzumab Plus Docetaxel in Chemotherapy-Refractory/Resistant Patients With Advanced Non-Small-Cell Lung Cancer
Biotech Pharmaceutical Co., Ltd.
CALC-1
National Cancer Institute, Naples
DOPERLO
Hellenic Cooperative Oncology Group
Pemetrexed +/- Carboplatin as Second Line Treatment in NSCLC
Gruppo Oncologico Italiano di Ricerca Clinica
Pilot Study for the Determination of Tumor Response to Chemotherapy in Advanced NSCLC Through Gene Expression Profiling
University of Michigan Rogel Cancer Center
Weekly Versus 3-Weekly Docetaxel Plus Cisplatin for Advanced NSCLC
Gachon University Gil Medical Center
Phase I Dose Escalation Study of VELCADE Plus Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors
Millennium Pharmaceuticals, Inc.